JSNM/JSNMT
日本語

PROGRAM

Keynote Lecture

Koichi TANAKA
Contributions to the early detection of Alzheimer’s disease using analytical and medical technologies

Koichi TANAKA

Mass Spectrometry Research Laboratory Shimadzu Corporation

CV
Brief Resume of past and present actives
Degree
1983. 3 B.A., Engineering, Tohoku University
Experience
1983. 4 Central Research Laboratory, Shimadzu Corporation.
1986. 5 Scientific Measurement Instru. Div., R&D Dep., Shimadzu Corp.
1992. 1 KRATOS Group PLC. in UK
1992.12 Analytical Instrument Division, R&D Department, Shimadzu Corporation
1997. 4 Shimadzu Research Laboratory (Europe) Ltd. in UK
1999.12 KRATOS Group PLC in UK
2002. 5 Analytical & Measuring Instru. Div., Life Sci. Busi. Unit, Shimadzu Corporation
2002.11 Fellow, Shimadzu Corporation
2003. 1 General Manager, Mass Spectrometry Research Lab., Shimadzu Corporation
2010. 3 General Manager, Koichi Tanaka Lab. of Advanced Science and Technology, Shimadzu Corporation
2012.6 Senior Fellow, Shimadzu Corporation
2020.4 Executive Research Fellow, Shimadzu Corporation
Honors & Awards
1989. 5 Encouragement Award from the Mass Spectroscopy Society of Japan
2002.11 Order of Cultural Merit Award
2002.12 Nobel Prize in Chemistry
Research fields

Development of tools and methods for analysis of protein and carbohydrate structure

Abstract
Abstract

The average life expectancy of human beings has increased significantly over the past several decades due to the improved performance of medical equipment and the tremendous efforts of medical professionals to keep cancer and cardiovascular diseases at bay. In order to further increase people’s healthy life expectancy, measures against dementia, especially Alzheimer’s disease (AD), which has become a global issue, are required.
Although therapeutic drugs are being developed for AD, there is a need to establish a simple and accurate method of detecting the disease at an early stage.
This lecture will outline the current status and future prospects for the development of ultra-early diagnosis and treatment methods, including therapeutic drugs, using early detection methods based on the analysis of trace amounts of blood using mass spectrometry, and the latest nuclear medicine imaging technology.

Plenary Lecture

Jean Luc Urbain

Jean Luc Urbain

Catholic University of Louvain

Ignasi Carrio

Ignasi Carrio

Autonomous University of Barcelona

Satoshi Minoshima

Satoshi Minoshima

Department of Radiology and Imaging Sciences at the University of Utah

Zhejiang University

Hong Zhang

Zhejiang University

Hisataka Kobayashi

Hisataka Kobayashi

National Institutes of Health

Richard P. Baum

Richard P. Baum

CURANOSTICUM Wiesbaden-Frankfurt at DKD Helios KlinikPresident Academy